Goldman Sachs Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $447

Benzinga Newsdesk www.benzinga.com Neutral 58.9%

Neg 0% Neu 58.9% Pos 0%

Goldman Sachs analyst Kevin Strang initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Price Target of $447.